Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck and Agensys to co-develop cancer antibody
Under the terms of the agreement, Merck will make an initial cash payment to Agensys of $17.5 million and, subject to the achievement of certain events, further payments
Under the terms of the agreement, Merck will make an initial cash payment to Agensys of $17.5 million and, subject to the achievement of certain events, further payments
The research, which appears in the journal Nature, describes a method of deriving stem cells in mice using a technique of single-cell embryo biopsy similar to that used
DDP225 is an orally-active compound that targets two key pathways that control the gastrointestinal system, thus giving it the potential to address multiple symptoms associated with diarrhea-predominant irritable
This study, part of the company’s broad oncology development program, will evaluate the safety, tolerability and initial response rates of MLN518 in combination with cytarabine and daunorubicin, the
Under the FDA modernization act of 1997, fast track designation allows the FDA to accept, on a rolling basis, portions of a marketing application prior to the completion
Antiplatelet agents prevent platelets from clumping or sticking together, which can cause formation of blood clots and lead to heart attack or stroke. Recent studies suggest that a
The first grant is a one-year “small business innovation research – advanced technology” (SBIR-AT) grant of $734,965, which will be used in the development of the company’s lead
The transaction provides MedImmune with three preclinical-stage programs developing monoclonal antibodies targeting the B-cell antigens CD19, CD20 and CD22. These antigens are believed to play important roles in
On February 28, 2005, Biogen Idec and Elan announced that they voluntarily suspended Tysabri from the US market and all ongoing clinical trials based on reports of progressive
The collaboration will focus on the optimization of lead compounds identified by Memory Pharmaceuticals and that have demonstrated effectiveness in the selective inhibition of PDE10 activity in several